Takeda Pharmaceutical Company Limited (TKPHF)
| Market Cap | 52.94B |
| Revenue (ttm) | 29.85B -2.8% |
| Net Income | 223.50M -88.6% |
| EPS | 0.14 -88.7% |
| Shares Out | n/a |
| PE Ratio | 236.87 |
| Forward PE | n/a |
| Dividend | 1.32 (4.25%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | n/a |
| Average Volume | 82,602 |
| Open | 31.12 |
| Previous Close | 31.12 |
| Day's Range | 31.12 - 31.12 |
| 52-Week Range | 24.94 - 32.13 |
| Beta | 0.04 |
| RSI | 57.96 |
| Earnings Date | Jan 29, 2026 |
About TKPHF
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livte... [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2025, TKPHF's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.
Financial numbers in JPY Financial StatementsNews
Takeda Announces US Availability Of GAMMAGARD LIQUID ERC For Primary Immunodeficiency Treatment
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK), Thursday announced the U.S. availability of GAMMAGARD LIQUID ERC, which is approved as a replacement therapy for people two years of age and ol...
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the U.S. availability of GAMMAGARD LIQUID™ ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA i...
Independence Bank of Kentucky Buys 201 Shares of Takeda Pharmaceutical Co Ltd (TAK)
Independence Bank of Kentucky Buys 201 Shares of Takeda Pharmaceutical Co Ltd (TAK)
Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Takeda Pharmaceutical, Protagonist Therapeutics Announces Submission Of NDA For Rusfertide
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK) and Protagonist Therapeutics, Inc. (PTGX), Monday announced the submission of a New Drug Application regarding rusfertide for the treatment of a...
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Applica...
Takeda's Once-Daily Psoriasis Pill Hits Phase 3 Goals, Beats Amgen's Drug
Takeda Pharmaceutical Co., Ltd (NYSE: TAK) on Thursday announced positive topline results for the two pivotal Phase 3 studies of zasocitinib (TAK-279) for moderate-to- severe plaque psoriasis (PsO) ....
Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using artificial intelligence, succeeded in two late-stage studies.
Takeda's Phase 3 Study Of Oral Zasocitinib In Plaque Psoriasis Achieves Primary Endpoints
(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK) Thursday reported that its Phase 3 studies of once-daily oral Zasocitinib met all primary and ranked secondary endpoints in adults with moderate-to-sev...
Takeda's Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda's Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment...
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from th...
Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies
SAN FRANCISCO and SUZHOU, China, Dec. 4, 2025 /PRNewswire/ -- Innovent Biologics (HKEX: 01801) today announced that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and...
US FDA investigates death tied to Takeda's blood disorder drug
The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder drug, the health regulator said on Friday.
Takeda blood disorder therapy Adzynma linked to patient death: FDA
Takeda Pharmaceutical (TAK) stock is in focus as the company's blood disease drug Adzynma is linked to a patient death, according to the FDA. Read more here.
Innovent, first Chinese firm to market weight-loss drug, joins Hang Seng Index
Innovent Biologics will join the Hang Seng Index next month in the latest quarterly review as the compiler of the city’s stock benchmark presses ahead with its plan to increase the number of constitue...
Beacon Biosignals Announces Multi-Year Expansion of Strategic Collaboration with Takeda to Advance Narcolepsy Diagnosis and Neurobiomarker Discovery
BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leading neurotechnology company powering AI-driven neurodiagnostics and precision medicines for the brain, today announced a multi-year e...
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile
On Monday, Neurocrine Biosciences, Inc. (NASDAQ: NBIX) said its Phase 2 study of NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint compared to placebo, though it ...
Takeda Shares Promising Interim Results For Mezagitamab In IgA Nephropathy
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK) announced new interim findings from its Phase 1b open-label proof-of-concept trial evaluating subcutaneous mezagitamab (TAK-079), an anti-CD38 m...
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079...
New Phase 3 Data Show Takeda's Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial...
Takeda Pharmaceutical Company Limited (TAK) Q2 FY2025 Earnings Call Transcript
Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript
Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges
Takeda Pharmaceutical Company Limited (NYSE: TAK) posted a second-quarter 2025 adjusted net profit of 201.6 billion Japanese yen (approximately $1.31 billion). The company reported earnings per Ameri...
Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges
Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a second-quarter 2025 adjusted net profit of 201.6 billion Japanese yen (approximately $1.31 billion).